ABUS vs JAZZ · P/E 5.4, rev $6.2M vs P/E 1988, rev $4.07B
Arbutus Biopharma Corp (ABUS) versus Jazz Pharmaceuticals PLC (JAZZ) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Not investment advice. Open the ABUS and JAZZ stock pages for the full models.
Not investment advice.